Activity Provided By:

ACHL

Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma

Overview / Abstract:	As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administration of bispecific antibodies for R/R MM. The content emphasizes the crucial role of the team in improving the timing and quality of treatment as well as facilitating equitable access. This education tailors learning to your needs, providing an ongoing reference tool to enhance care in this complex landscape.
Expiration	Mar 18, 2025
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME
Format	Online, Webinar / Webcast / Video, Workbook
Credits / Hours	1.0 hours
Accreditation	ACCME, ACPE, ANCC
Presenters / Authors / Faculty	Beth Faiman PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO Cleveland Clinic Taussig Cancer Institute Department of Hematology and Medical Oncology Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center Cleveland Clinic Cleveland, OH Rebecca LaRue, PharmD, BCOP Clinical Pharmacy Specialist Hematology/Oncology/Cellular Therapy Team Lead Hematology/Oncology Pharmacy Rush University Medical Center Chicago, IL Surbhi Sidana, MD Assistant Professor of Medicine Director, Myeloma Cellular Immunotherapy & Myeloma Disease Focused Group Division of BMT & Cell Therapy Stanford University Stanford, CA
Sponsors / Supporters / Grant Providers	This educational activity is presented in collaboration with Rush University Medical Center and Academy for Continued Healthcare Learning (ACHL). Supported by an educational grant from Pfizer, Inc.
Keywords / Search Terms	ACHL Digital practice guide, cancer care, relapsed, refractory, multiple myeloma, RRMM, treatment-related toxicity, comorbidities, multidisciplinary oncology team, bispecific antibodies, bispecific antibodies for R/R MM, biomarkers, oncology, comorbidities, sequencing therapies, disease progression, hematologic malignancy, refractory (R/R) disease, BCMA, GPRC5D, elranatamab, teclistamab, talquetamab Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map